Company: DMAC
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016488
Chunk: 5

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part II, Item 1A
Chunk 5
---
 ended March 31, 2025.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and Modifications

During the three months ended March 31, 2025, noneof our directors or “officers” (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “ Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) and 408(c), respectively, of SEC Regulation S-K.

ITEM 6. EXHIBITS

The following exhibits are being filed or furnished with this quarterly report on Form 10-Q:

  Exhibit      Description                                                                                                                                                                                               Manner of Filing                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                       
      No.                                                                                                                                                                                                                                                                                                                                                                                              
      3.1      Notice of Articles of DiaMedica Therapeutics Inc. dated June 16, 2023                                                                                                                                     Incorporated by reference to Exhibit 3.1 to DiaMedica’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 (File No. 001-36291)                  
     10.1      Letter Agreement dated as of January 28, 2025 between DiaMedica Therapeutics Inc. and Lorianne Masuoka, M. D.                                                                                             Filed herewith                                                                                                                                                                
      101      Financial statements from the quarterly report on Form 10-Q of DiaMedica Therapeutics Inc. for the three months ended March 31, 2025, formatted in Inline XBRL: (i) the Condensed Consolidated Ba...      Filed herewith                                                                                                                                                                
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      3.2      Amended and Restated Articles of DiaMedica Therapeutics Inc. Effective May 17, 2023                                                                                                                       Incorporated by reference to Exhibit 3.1 to DiaMedica’s Current Report on Form 8-K as filed with the Securities and Exchange Commission on May